Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvimopan - Merck

Drug Profile

Alvimopan - Merck

Alternative Names: ADL 8-2698; ADL2698; Entereg; Entrareg; LY 246736

Latest Information Update: 24 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Adolor Corporation; Merck & Co
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postoperative ileus
  • Discontinued Constipation; Irritable bowel syndrome

Most Recent Events

  • 13 Apr 2016 Merck Sharp & Dohme and University Hospital Case Medical Center plan a phase III trial for Postoperative ileus in USA (PO) (NCT02742181)
  • 01 Jul 2015 Cubist Pharmaceuticals initiates enrolment in a phase II trial for Postoperative ileus in USA (NCT02379858)
  • 18 Mar 2015 Cubist Pharmaceuticals plans a phase II trial for Postoperative ileus in USA (NCT02379858).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top